M
Maureen M. Jonas
Researcher at Boston Children's Hospital
Publications - 194
Citations - 11977
Maureen M. Jonas is an academic researcher from Boston Children's Hospital. The author has contributed to research in topics: Hepatitis C & Hepatitis C virus. The author has an hindex of 47, co-authored 191 publications receiving 9826 citations. Previous affiliations of Maureen M. Jonas include Harvard University & Seattle Genetics.
Papers
More filters
Journal ArticleDOI
Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance
Norah A. Terrault,Anna S. Lok,Brian J. McMahon,Kyong-Mi Chang,Jessica P. Hwang,Maureen M. Jonas,Robert S. Brown,Natalie Bzowej,John B. Wong +8 more
TL;DR: This AASLD 2018 Hepatitis B Guidance provides a data-supported approach to screening, prevention, diagnosis, and clinical management of patients with hepatitis B.
Journal ArticleDOI
AASLD guidelines for treatment of chronic hepatitis B
Norah A. Terrault,Natalie Bzowej,Kyong-Mi Chang,Jessica P. Hwang,Maureen M. Jonas,M. Hassan Murad +5 more
TL;DR: Aasld Guidelines for Treatment of Chronic Hepatitis B Norah Terrault;Natalie Bzowej;Kyong-Mi Chang;Jessica Hwang;Maureen Jonas;Hassan Murad; Hepatology
Journal ArticleDOI
Acute liver failure in children: The first 348 patients in the pediatric acute liver failure study group
Robert H. Squires,Benjamin L. Shneider,John C. Bucuvalas,Estella M. Alonso,Ronald J. Sokol,Michael R. Narkewicz,Anil Dhawan,Philip J. Rosenthal,Norberto Rodriguez-Baez,Karen F. Murray,Simon Horslen,Martin G. Martin,M. James Lopez,Humberto Soriano,Brendan M. McGuire,Maureen M. Jonas,Nada Yazigi,Ross W. Shepherd,Kathleen B. Schwarz,Steven J. Lobritto,Daniel W. Thomas,Joel E. Lavine,Saul J. Karpen,Vicky L. Ng,Deirdre Kelly,Nancy Simonds,Linda S. Hynan +26 more
TL;DR: To determine short-term outcome for children with acute liver failure (ALF) as it relates to cause, clinical status, and patient demographics and to determine prognostic factors, a prospective, multicenter case study on children from birth to 18 years with ALF is conducted.
Journal ArticleDOI
Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection
Raymond T. Chung,Marc G. Ghany,Arthur Y. Kim,Kristen M. Marks,Susanna Naggie,Hugo E. Vargas,Andrew Aronsohn,Debika Bhattacharya,Tina Broder,Oluwaseun Falade-Nwulia,Robert J. Fontana,Stuart C. Gordon,Theo Heller,Scott D. Holmberg,Ravi Jhaveri,Maureen M. Jonas,Jennifer J. Kiser,Benjamin P. Linas,Vincent Lo Re,Timothy R. Morgan,Ronald Nahass,Marion G. Peters,K. Rajender Reddy,Andrew Reynolds,John D. Scott,Gloria Searson,Tracy Swan,Norah A. Terrault,Stacey Trooskin,John B. Wong,Kimberly A. Workowski +30 more
TL;DR: This update summarizes the latest release of the HCV guidance and focuses on new or amended recommendations since the previous September 2015 print publication.
Journal ArticleDOI
Clinical trial of lamivudine in children with chronic hepatitis B.
Maureen M. Jonas,Deirdre A. Kelley,J. Mizerski,Isabel B. Badia,Jorge A. Areias,Kathleen B. Schwarz,Nancy R. Little,Martin J. Greensmith,Stephen D. Gardner,M. Steve Bell,Etienne Sokal +10 more
TL;DR: In children with chronic hepatitis B, 52 weeks of treatment with lamivudine was associated with a significantly higher rate of virologic response than was placebo and was also associated with higher rates of seroconversion from hepatitis B e antigen to hepatitis B E antibody, normalization of alanine aminotransferase levels, and suppression of HBV DNA.